News >

KD025 Hits High Response Rate in Chronic GVHD

Gina Columbus @ginacolumbusonc
Published: Tuesday, Nov 12, 2019

Corey Cutler, MD, MPH, FRCPC, associate professor of medicine, Harvard Medical School, and medical director of the Adult Stem Cell Transplantation Program, Dana-Farber Cancer Institute

Corey Cutler, MD, MPH, FRCPC

Treatment with the selective ROCK2 inhibitor KD025 led to statistically significant overall response rates (ORRs) in patients with chronic graft-versus-host disease (cGVHD) who have received ≥2 prior lines of systemic therapy, meeting the primary endpoint at an interim analysis of the phase II ROCKstar trial (KD025-213; NCT03640481).1

Cytokines (IL-21, IL-17) regulated by the ROCK2 signaling pathway play an integral role in the pathogenesis of cGVHD. Clinical research has demonstrated that inhibiting the ROCK2 pathway reduces the pathogenesis of cGVHD.

References

  1. Kadmon announces that KD025 met primary endpoint at interim analysis of pivotal trial in chronic graft-versus-host disease. Kadmon Holdings, Inc. Published November 11, 2019. https://bit.ly/2pWygUc. Accessed November 12, 2019.
  2. Lazaryan A, Lee SJ, Salhotra A, et al. Initial results of KD025-208: a phase 2a open-label clinical trial of KD025 for steroid-dependent chronic graft versus host disease (cGVHD). Biol Blood Marrow Transplant. 2018;24(3):S25-S118. doi: 10.1016/j.bbmt.2017.12.615.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x